Payment overview · 2025
General Payments
$695.57
32 reported records · 8 companies
Healthcare provider profile · identity verified
Andrew John Bartlett, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JACKSON, MS · NPI 1477932770
Verified facts
What the public records show
CMS Open Payments records show Andrew John Bartlett, M.D. received $695.57 in general payments during 2025 across 32 reported records.
AstraZeneca Pharmaceuticals LP accounted for 69.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $486.34 | 69.9% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.14 | 7.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $45.82 | 6.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.51 | 5.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.25 | 3.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.72 | 2.7% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.69 | 2.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.10 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $695.57 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $371.04 | 16 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $65.38 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.14 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $54.14 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $45.82 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $36.51 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $26.64 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 136 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 169 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
136 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
60 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
177 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
67 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
177 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
106 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
169 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1340 | 294 |
| Pantoprazole Sodium | Pantoprazole Sodium | 796 | 187 |
| Metformin Hcl | Metformin Hcl | 723 | 173 |
| Furosemide | Furosemide | 696 | 160 |
| Carvedilol | Carvedilol | 649 | 164 |
| Atorvastatin Calcium | Atorvastatin Calcium | 576 | 128 |
| Pravastatin Sodium | Pravastatin Sodium | 548 | 124 |
| Gabapentin | Gabapentin | 546 | 140 |
| Potassium Chloride | Potassium Chloride | 535 | 125 |
| Losartan Potassium | Losartan Potassium | 522 | 117 |
| Hydrochlorothiazide | Hydrochlorothiazide | 510 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 408 | 110 |
| Lisinopril | Lisinopril | 395 | 95 |
| Metoprolol Tartrate | Metoprolol Tartrate | 385 | 88 |
| Omeprazole | Omeprazole | 343 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 342 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 327 | 74 |
| Glipizide | Glipizide | 315 | 75 |
| Fluticasone Propionate | Fluticasone Propionate | 293 | 96 |
| Meloxicam | Meloxicam | 292 | 69 |
| Montelukast Sodium | Montelukast Sodium | 269 | 57 |
| Hydralazine Hcl | Hydralazine Hcl | 262 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 254 | 58 |
| Diclofenac Sodium | Diclofenac Sodium | 240 | 72 |
| Eliquis | Apixaban | 229 | 47 |
| Allopurinol | Allopurinol | 228 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 51 |
| Famotidine | Famotidine | 200 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 191 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 189 | 46 |
| Simvastatin | Simvastatin | 187 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 186 | 38 |
| Jardiance | Empagliflozin | 177 | 34 |
| Ozempic | Semaglutide | 169 | 27 |
| Clonidine Hcl | Clonidine Hcl | 168 | 42 |
| Linzess | Linaclotide | 162 | 44 |
| Entresto | Sacubitril/Valsartan | 159 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 156 | 43 |
| Farxiga | Dapagliflozin Propanediol | 136 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 133 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 123 | 32 |
| Trulicity | Dulaglutide | 106 | 19 |
| Lovastatin | Lovastatin | 104 | 22 |
| Warfarin Sodium | Warfarin Sodium | 104 | 20 |
| Trazodone Hcl | Trazodone Hcl | 101 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 101 | 46 |
| Spironolactone | Spironolactone | 98 | 28 |
| Nifedipine Er | Nifedipine | 97 | 22 |
| Atenolol | Atenolol | 96 | 23 |
| Colchicine | Colchicine | 94 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 16 |
| Januvia | Sitagliptin Phosphate | 84 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | 15 |
| Finasteride | Finasteride | 82 | 19 |
| Glimepiride | Glimepiride | 81 | 18 |
| Sertraline Hcl | Sertraline Hcl | 81 | 17 |
| Tradjenta | Linagliptin | 81 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 13 |
| Benazepril Hcl | Benazepril Hcl | 65 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | 14 |
| Ezetimibe | Ezetimibe | 64 | 20 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 62 | 18 |
| Nitroglycerin | Nitroglycerin | 62 | 20 |
| Meclizine Hcl | Meclizine Hcl | 60 | 21 |
| Symbicort | Budesonide/Formoterol Fumarate | 60 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 53 |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 49 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 16 |
| Donepezil Hcl | Donepezil Hcl | 56 | 12 |
| Glipizide Er | Glipizide | 55 | 13 |
| Levetiracetam | Levetiracetam | 55 | 15 |
| Baclofen | Baclofen | 53 | 13 |
| Mirtazapine | Mirtazapine | 53 | 18 |
| Myrbetriq | Mirabegron | 53 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | suppressed |
| Pregabalin | Pregabalin | 53 | 13 |
| Chlorthalidone | Chlorthalidone | 52 | 16 |
| Xarelto | Rivaroxaban | 52 | 12 |
| Buspirone Hcl | Buspirone Hcl | 50 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | 13 |
| Prednisone | Prednisone | 50 | 24 |
| Tramadol Hcl | Tramadol Hcl | 49 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 47 | suppressed |
| Ibuprofen | Ibuprofen | 46 | 21 |
| Alendronate Sodium | Alendronate Sodium | 45 | 13 |
| Digoxin | Digoxin | 45 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 15 |
| Topiramate | Topiramate | 42 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | 12 |
| Azelastine Hcl | Azelastine Hcl | 39 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 39 | 12 |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 37 | suppressed |
| Mitigare | Colchicine | 36 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | 11 |
| Bumetanide | Bumetanide | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 34 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | 13 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 29 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | 12 |
| Fluconazole | Fluconazole | 28 | 17 |
| Indapamide | Indapamide | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 25 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | 11 |
| Metolazone | Metolazone | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 13 |
| Phenobarbital | Phenobarbital | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 20 | suppressed |
| Febuxostat | Febuxostat | 20 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 17 |
| Lidocaine | Lidocaine | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 16 |
| Alprazolam | Alprazolam | 17 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 15 |
| Methylprednisolone | Methylprednisolone | 15 | 14 |
| Mupirocin | Mupirocin | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Zafirlukast | Zafirlukast | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Climara Pro | Estradiol/Levonorgestrel | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Probenecid | Probenecid | 11 | suppressed |
| Victoza 2-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $695.57 · 32 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, MOUNJARO, NUZYRA, Ozempic, Rybelsus, TRELEGY ELLIPTA, XHANCE, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error